Corporate Profile
We are a specialty pharmaceutical company focused on developing proprietary products to treat multiple diseases within the inflammation pathway, primarily, but not exclusively, by the use of Cytac™, a novel carbonyl-trapping agent. Our goal is to turn cellular health into a clinical reality, for healthy cells enable the body to rid itself of toxic agents that cause underlying cellular damage.
At Zylera, we recognize that physicians are seeking new prescription tools they can use with confidence to advance treatment with more positive outcomes for the patient. Studies indicate that the chemical compounds constituting Zylera’s products have been shown to create a positive impact on cellular response and patient health.
Our near-term pipeline includes products to treat diabetes, high cholesterol, osteoporosis, and osteoarthritis. These products are designed to restore metabolic processes that have shifted due to specific problems or age-related diseases. Zylera, founded in 2005, is headquartered in Research Triangle Park, NC.
Aging and diseases related to aging are accelerated by complex chemical processes through which the structure of a protein is warped by exposure to reactive molecules, like sugar. To combat these processes and slow, or in some instances prevent, these complex chemical processes triggering unhealthy biochemical signaling in your cells and damaging your DNA, Zylera has secured the exclusive license to a pioneering technology that works as a carbonyl trapping agent to rid the body of the chemical handcuffs created when proteins interact negatively with certain reactive molecules.
This patented technology, called Cytac™, is an essential component of several of our proprietary pharmaceutical products and allows other active ingredients in these products to be more efficient and effective at treating diseases associated with aging, such as diabetes, high cholesterol and osteoarthritis.